Full exclusively enteral fluids from day 1 versus gradual feeding in preterm infants (FEED1): a open-label,

Shalini Ojha1, Eleanor J Mitchell1, Mark J Johnson2

  • 1School of Medicine, University of Nottingham, Nottingham, UK.

Insights

Starting full milk feeds on day 1 for preterm infants (30-32 weeks gestation) did not shorten hospital stays. This feeding strategy also did not increase risks of necrotising enterocolitis or hypoglycaemia.

Area of Science:

  • Neonatal Medicine
  • Pediatric Gastroenterology
  • Clinical Nutrition

Background:

  • Preterm infants typically receive gradual milk feeds alongside intravenous fluids or parenteral nutrition.
  • Early milk feeding may reduce hospital stay and infection risk but could increase necrotising enterocolitis risk.

Purpose of the Study:

  • To investigate if exclusively enteral fluids (full milk feeds) from day 1, compared to gradual milk feeding, reduces hospital stay in preterm infants (30-32 weeks gestation).

Main Methods:

  • An open-label, multicentre, randomised superiority trial involving 2088 infants born between 30+0 and 32+6 weeks gestation.
  • Infants were randomly assigned within 3 hours of birth to either full milk feeds (60-80 mL/kg/day) or gradual milk feeding (max 30 mL/kg/day on day 1) with IV support.
  • Primary outcome was length of hospital stay; safety outcomes included necrotising enterocolitis and hypoglycaemia. Intention-to-treat analysis was performed.

Main Results:

  • No significant difference in the length of hospital stay between the full milk feeds group (32.4 days) and the gradual feeding group (32.1 days).
  • Similar rates of survival to discharge, necrotising enterocolitis, and hypoglycaemia events were observed in both groups.
  • Serious adverse events were infrequent and similar between the groups, with no reported relation to the trial intervention.

Conclusions:

  • Initiating full milk feeds from day 1 in preterm infants (30-32 weeks gestation) does not alter hospital length of stay.
  • This early feeding strategy does not increase the risk of necrotising enterocolitis or hypoglycaemia.
  • Current feeding guidelines for this preterm infant population can be maintained without increasing adverse outcomes.
Abstract

Related Concept Videos

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding01:15

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
814
Enteral Nutrition I: Orogastric and Nasogastric Feeding01:26

Enteral Nutrition I: Orogastric and Nasogastric Feeding

Enteral nutrition delivers nutrients directly to the stomach or small intestine through a tube. This method is appropriate for patients who cannot eat but still have a functioning digestive system. It is also beneficial for individuals with swallowing difficulties, anorexia, malabsorption, or those who have undergone gastrointestinal (GI) surgery.
Orogastric (OG) and nasogastric (NG) feeding are two standard methods used for enteral nutrition. Enteral nutrition is often preferred over...
1.2K
Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
293
One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance00:56

One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance

Clearance is a key pharmacokinetic parameter that quantifies the volume of body fluid from which a drug is entirely removed within a specific time frame. It is crucial in assessing how a drug is eliminated from the body and has critical clinical applications.
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
340
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
143
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
205